MENU
+Compare
NGENF
Stock ticker: OTC
AS OF
May 22 closing price
Price
$3.95
Change
-$0.77 (-16.31%)
Capitalization
279.23M

NGENF NervGen Pharma Corp. Forecast, Technical & Fundamental Analysis

NervGen Pharma Corp is a clinical-stage biotech company... Show more

NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for NGENF with price predictions
May 22, 2025

Momentum Indicator for NGENF turns positive, indicating new upward trend

NGENF saw its Momentum Indicator move above the 0 level on April 21, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned positive. In of the 95 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where NGENF advanced for three days, in of 244 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 128 cases where NGENF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for NGENF moved out of overbought territory on May 22, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NGENF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NGENF broke above its upper Bollinger Band on May 16, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NGENF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NGENF's P/B Ratio (285.714) is very high in comparison to the industry average of (16.302). P/E Ratio (0.000) is within average values for comparable stocks, (59.789). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.190). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (277.726).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
NGENF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
112-970 Burrard Street
Phone
+1 778 731-1711
Employees
N/A
Web
https://www.nervgen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CODI7.360.11
+1.52%
Compass Diversified
VANI1.140.01
+0.88%
Vivani Medical
MED13.24N/A
N/A
Medifast
ALSN103.84N/A
N/A
Allison Transmission Holdings
TTE58.16-0.67
-1.14%
TotalEnergies SE

NGENF and Stocks

Correlation & Price change

A.I.dvisor tells us that NGENF and CYTK have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NGENF and CYTK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGENF
1D Price
Change %
NGENF100%
-16.31%
CYTK - NGENF
25%
Poorly correlated
-2.63%
IBRX - NGENF
23%
Poorly correlated
+1.13%
TNFA - NGENF
22%
Poorly correlated
N/A
CARM - NGENF
22%
Poorly correlated
+4.78%
ATRA - NGENF
22%
Poorly correlated
N/A
More